Approximately one in five subjects (19.3%) reported no side effects
Side effects are most likely to appear after beginning the medication or after a dose increase
Last reviewed: June 3, 2026 Last updated: June 3, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
These medications include semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro, Zepbound)though tirzepatide is technically a dual GIP/GLP-1 receptor agonist with a slightly different mechanism
Even before enactment, FDA and state attorneys general are already intensifying enforcement against misleading marketing and unsafe compounding practices
April 2026